drugset / Trial / NCT00386399
Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Phase 2
Withdrawn
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Van Andel Research Institute · collab
NaSingle-groupOpen-labelDiagnostic
Summary
Patients will be tested for mutations in the BRCA2 gene. If they have a BRCA2 mutation, they will be treated with Mitomycin-C as described here. The patients with an identified gene mutation will also be provided with genetic counseling.
Timeline
- Start
- 2006-10
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitomycin C | Other / unclassified | 10 mg/m2 | Intravenous |